Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of intangible assets

Other operating expense (income), net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Quest Diagnostics

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Quest Diagnostics reports robust 2022 performance amidst COVID-19 testing decline

Quest Diagnostics delivered strong financial performance in 2022, with revenue growth and strategic acquisitions driving expansion.
Challenges include the anticipated decline in COVID-19 testing revenues and regional healthcare recovery disparities post-pandemic.
Opportunities lie in advanced diagnostics investments, productivity enhancements, and upcoming investor day to showcase growth strategies.
Overall, Quest Diagnostics remains focused on long-term growth, margin improvement, and shareholder value creation.

Quest Diagnostics reports strong Q1 earnings, eyes growth opportunities

Quest Diagnostics' Q1 performance reflects robust revenue growth and strategic acquisitions positioning the company for future success. Challenges in margin progression and market expectations for MRD testing require attention, while opportunities in oncology distribution and consumer testing optimization offer avenues for growth.

Quest Diagnostics reports robust Q2 earnings, raises guidance amid challenges

Quest Diagnostics demonstrated strong financial performance in Q2 2023, with revenue growth, margin improvement, and raised guidance, despite challenges like high turnover and labor costs.
The company's strategic focus on innovation, acquisitions, and pricing strategies presents opportunities for sustained growth and market expansion in clinical areas like genomics and oncology.
Navigating challenges related to employee turnover and cost pressures while leveraging opportunities in M&A, value-based care, and technological advancements will be crucial for Quest Diagnostics' future success.

Quest Diagnostics reports robust Q3 earnings amidst COVID challenges

Quest Diagnostics delivered strong financial results in Q3, showcasing growth in base business and adjusted EPS. While facing challenges from COVID-19 testing revenue decline and regulatory uncertainties, the company remains focused on leveraging opportunities in growth investments and margin improvements.

Quest Diagnostics reports robust 2023 performance and optimistic 2024 outlook

Quest Diagnostics delivered strong financial performance in 2023, with revenue growth driven by acquisitions and strategic initiatives.
The company's focus on oncology, Alzheimer's offerings, and AI tools deployment positions them for continued growth and innovation.
While facing short-term challenges like regulatory uncertainties and pricing pressures, Quest Diagnostics remains confident in their long-term outlook and growth prospects.
With a positive guidance for 2024, including revenue and EPS expectations, the company aims to navigate headwinds and capitalize on opportunities for sustainable growth.

Quest Diagnostics reports robust Q1 results and strategic growth plans

Quest Diagnostics' Q1 performance showcased strong revenue growth and strategic investments in advanced diagnostics and automation.
While facing challenges like regulatory concerns and pricing pressures, the company's focus on acquisitions and operational efficiency drives growth.
Opportunities lie in continued automation efforts, market expansion in advanced diagnostics, and the positive outlook for key acquisitions.
Overall, Quest Diagnostics' solid financial results and raised guidance reflect a resilient business poised for future growth.

Quest Diagnostics reports robust Q2 earnings amid strategic acquisitions

Quest Diagnostics' Q2 2024 performance reflects solid revenue growth, operational efficiency, and strategic acquisitions driving expansion.
Despite challenges related to acquisition impact on EPS and industry dynamics, Quest's strong balance sheet and growth strategy position it well for the future.
The company's focus on advanced diagnostics, financial stability, and market opportunities underscores its resilience and growth potential in the healthcare sector.

Quest Diagnostics reports strong Q3 growth driven by acquisitions and advanced diagnostics

Quest Diagnostics' Q3 2024 performance reflects a robust growth trajectory driven by strategic acquisitions and a focus on advanced diagnostics.
While facing integration challenges and market uncertainties, the company's strong revenue streams and operational initiatives position it well for future growth.
With a reaffirmed long-term outlook and proactive acquisition strategy, Quest Diagnostics remains poised for continued success in the healthcare diagnostics sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings Inc

Allscripts Healthcare Solutions

PRA Health Sciences

Thermo Fisher Scientific

Veeva Systems

Zoom Video

Asian countries have already shown clear signs of major economic recession.

Is Another Great Depression Imminent or Is it Just a Myth?

Shares of Quest Diagnostics Inc. were down 0.4% in premarket trading on Thursday after the company said it will sell a COVID-19 diagnostic test directly to consumers to use at home.

Quest to offer at-home test for COVID-19 infections

SECAUCUS, N.J., Sept. 17, 2020 /PRNewswire/ -- Individuals can now purchase a test to diagnose COVID-19 online, without visiting a doctor's office, through QuestDirect, the consumer-initiated testing business of Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic.

Quest Diagnostics Now Offers Two Consumer-Initiated and Physician-Ordered COVID-19 Diagnostic Test Options for Active COVID-19 Infection Through QuestDirect™

Quest Diagnostics (DGX) closed the most recent trading day at $113.59, moving +0.77% from the previous trading session.

Quest Diagnostics (DGX) Outpaces Stock Market Gains: What You Should Know

SECAUCUS, N.J., Sept. 11, 2020 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley 18th Annual Global Healthcare Conference.

Quest Diagnostics To Speak At The Morgan Stanley 18th Annual Healthcare Conference

Quest Diagnostics (DGX) stock has sold off after failing the July breakout and could enter a new downtrend in coming weeks.

Quest Diagnostics (DGX) Could Enter New Downtrend

Shares of Quest Diagnostics Inc. DGX, -0.32% were indicated up 1% in premarket trading Thursday, after the health care diagnostics company raised its full-year outlook for profit and revenue, citing a faster-than-anticipated recovery in testing volumes through the end of August.

Quest Diagnostics stock set to rise after profit, revenue outlook raised

Applied Materials

American Express

Carrier Global

Capital One

Raytheon Technologies

Wells Fargo

Please provide your current perspective on the market during COVID-19:

Chris Davis' Davis New York Venture Fund Fall 2020 Review

WASHINGTON, Sept. 8, 2020 /PRNewswire/ -- If there is a silver lining to be found in the ongoing COVID-19 crisis, it may be the increased attention employers are placing on the need to protect and promote employee health and well-being.

Quest Diagnostics Receives C. Everett Koop National Health Award for Efforts to Promote Employee Health and Business Results

Hologic

QuidelOrtho Corp

These three stocks have consolidated their strong competitive positions in recent months.

3 Lucrative Coronavirus Testing Stocks to Buy Right Now

Emerson Electric

General Dynamics

Public Storage

Republic Services

With the third quarter of 2020 almost over, many of the top companies we follow on Wall Street are making some changes to the curated lists of stock picks for clients.

BofA Securities Makes Big Fall Changes to High Quality & Dividend Yield Portfolio

SECAUCUS, N.J., Sept. 3, 2020 /PRNewswire/ -- The rate at which women 18-30 years of age tested positive for the two most common reportable sexually transmitted infections grew by double digits between 2010 and 2017, finds an analysis of nearly 18 million de-identified test results from.

Chlamydia and Gonorrhea Positivity Surges in Women Ages 18-30 Years, Finds Quest Diagnostics Health Trends Study

SECAUCUS, N.J., Sept. 2, 2020 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Wells Fargo Virtual Healthcare Conference.

Quest Diagnostics To Speak At The 2020 Wells Fargo Virtual Healthcare Conference

Can the diagnostics and testing company be a reliable income producer for your portfolio?

Is Quest Diagnostics a Great Dividend Stock?

Rival Abbott is looking to become the dominant player in the coronavirus test arena.

Here's Why Quidel, Hologic, and Quest Diagnostics Shares Fell Today

SECAUCUS, N.J., Aug. 25, 2020 /PRNewswire/ -- The rate of workforce drug positivity hit a sixteen-year high in 2019, according to a new analysis released today by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services.

Workforce Drug Testing Positivity Climbed to Highest Rate in 16 Years, New Quest Diagnostics Drug Testing Index™ Analysis Finds

SECAUCUS, N.J., Aug. 24, 2020 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, and the Quest Diagnostics Foundation, today announced a wide-ranging initiative to address and reduce health disparities in.

Quest Diagnostics and Quest Diagnostics Foundation Launch Initiative to Reduce Health Disparities in Underserved Communities

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?

Why Is Quest Diagnostics (DGX) Down 7.7% Since Last Earnings Report?

Quest Diagnostics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
The post Stocks With Rising Relative Strength: Quest Diagnostics appeared first on Investor's Business Daily.

Stocks With Rising Relative Strength: Quest Diagnostics

A limited supply of the right kinds of Covid-19 tests has hampered the U.S. response to the coronavirus since the very beginning, public health specialists say.

Quest Diagnostics says it cut coronavirus testing turnaround to one to two days, but warns it could slip

INDIANAPOLIS and SECAUCUS, N.J., Aug. 17, 2020 /PRNewswire/ -- Anthem Inc.

Anthem and Quest Diagnostics Form Strategic Relationship

SECAUCUS, N.J., Aug. 12, 2020 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, today released its Annual Environmental, Social & Governance Report for 2019.

Quest Diagnostics Releases Annual Environmental, Social & Governance Report

Quest Diagnostics: A Steady Investment Opportunity Buoyed By Current Market Tailwinds

Quest Diagnostics Completes Acquisition of Mid America Clinical Laboratories, Now Provides Professional Lab Management for Nearly 30 Hospitals of Community Health Network and Ascension St. Vincent in Indiana

SECAUCUS, N.J., Aug. 3, 2020 /PRNewswire/ -- A new innovation in advanced genetic sequencing automation from Quest Diagnostics (NYSE: DGX) will now enable individuals to access highly accurate genetic testing providing insights into inherited diseases including cancers of the breast,.

News for Quest Diagnostics Stock (DGX)